GlassScriptPhysician profile
Mitul V Patel
NPI 1689104341
$15,242.33
in general payments reported to CMS, 2019-2025
25 companies · $2,208 in 2025
The $2,208 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $302 · 2021: $1,415 · 2022: $1,538 · 2023: $3,996 · 2024: $5,609 · 2025: $2,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,617 · Travel and Lodging: $3,338 · Grant: $1,692 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,617.15 |
| Travel and Lodging | $3,338.19 |
| Grant | $1,692.30 |
| Education | $165.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,391.47 | 2019-2024 | Avvigo Guidance System, Rotapro, Latitude Communicator Power Supply |
| Abbott Laboratories | $2,412.25 | 2021-2025 | Aveir, Navitor, Assurity |
| Medtronic, INC. | $2,032.42 | 2021-2025 | Corevalve Evolut R, Endurant Iis, Onyx Frontier |
| Edwards Lifesciences Corporation | $1,947.77 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Penumbra, INC. | $1,510.72 | 2024-2025 | Indigo System, Ruby Coil |
| Inari Medical, INC. | $814.47 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abiomed | $608.67 | 2024-2025 | Impella |
| Cardiovascular Systems INC. | $507.92 | 2020-2023 | Diamondback Peripheral |
| Terumo Medical Corporation | $403.78 | 2022-2024 | Glidewire, Angio-Seal, R2p Misago |
| Shockwave Medical, INC | $321.35 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.43 | 2024-2025 | Lifevest |
| Stryker Corporation | $165.74 | 2025 | Flowtriever |
| Atricure, INC. | $162.72 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Atricure Cryoice Cryoablation System (Cryo2) |
| Cardiva Medical, INC. | $127.77 | 2023-2024 | Cardiva Vascade 5f Vcs, Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Astrazeneca Pharmaceuticals LP | $124.22 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $111.26 | 2023 | Camzyos |
| Kestra Medical Technology Services, INC. | $100.95 | 2024-2025 | Assure Wcd |
| Ekos Corporation | $96.50 | 2019 | |
| Abbvie INC. | $50.00 | 2024 | |
| Pfizer INC. | $44.66 | 2023 | |
| Recor Medical INC | $42.96 | 2024 | Paradise Renal Denervation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.16 | 2019 | |
| Janssen Biotech, INC. | $29.89 | 2025 | Tremfya |
| Glaxosmithkline, LLC. | $20.79 | 2025 | Trelegy Ellipta |
| Ucb, INC. | $15.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitul Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.